Loading
Latest filing published 20 May 2022 for RVL Pharmaceuticals plc, €7,282.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Tina Marie deVries, listed as senior executive, appears in our data through filings on RVL Pharmaceuticals plc shares, published by SEC (Form 4). Between 24 January 2019 and 18 May 2022, the trades on record add up to 7 filings.
The filings describe grants, exercises and other transfers rather than trades on the open market. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
The record was last updated on 20 May 2022 with a share grant (€7,282) in RVL Pharmaceuticals plc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations